Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route.
Information on antibody persistence after aerosol revaccination with MMR components is limited. Thus, antibody titers were determined in 283 adult participants in a MMR vaccine trial 12 months after revaccination. One group had received aerosolized Triviraten vaccine while two other groups received either injected Triviraten or MMR II vaccine. Both MMR vaccines contained the same rubella strain, but different measles and mumps strains. Seropositivity to measles persisted in 98% of aerosolized vaccine recipients, 92% of injected Triviraten, and 95% of injected MMR II. All participants in the three groups retained seropositivity to rubella, while less than 50% remained seropositive to mumps.
Díaz-Ortega
José Luis
JL
Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública (INSP), Ave. Universidad No. 655, Colonia Santa María Ahuacatitlán, 62100 Cuernavaca, Morelos, Mexico. jdiaz@correo.insp.mx
Bennett
John V
JV
Castañeda
D
D
Martinez
D
D
de Castro
J Fernandez
JF
D000280:Administration, Inhalation; D000336:Aerosols / Q000008:administration & dosage; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006801:Humans; D007114:Immunization / Q000379:methods*; D008297:Male; D008457:Measles / Q000276:immunology / Q000517:prevention & control; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology*; D009107:Mumps / Q000276:immunology / Q000517:prevention & control; D012409:Rubella / Q000276:immunology / Q000517:prevention & control; D055815:Young Adult
D000336:Aerosols; D000914:Antibodies, Viral; D022542:Measles-Mumps-Rubella Vaccine